AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16881243 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation tool for evaluating parent-child interaction; details on dosage and duration not applicable.
Number of subjects: 0
Study 12953740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat (ITT) analysis
Number of subjects: 28
Study 12953740 — intervention group
Group type: COMPARATOR
Intervention: Protocol deviations
Number of subjects: 28
Study 11202321 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed treatment
Number of subjects: 136
Study 11202321 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment
Number of subjects: 136
Study 11202321 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 8985844 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula beta (24% palmitic acid, 66% esterified to beta-position)
Number of subjects: 27
Study 8985844 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula intermediate (24% palmitic acid, 39% esterified to beta-position)
Number of subjects: 27
Study 8985844 — intervention group
Group type: COMPARATOR
Intervention: Regular formula (20% palmitic acid, 13% esterified to beta-position)
Number of subjects: 27
Study 8985844 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula beta
Number of subjects: 27
Study 8985844 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula intermediate
Number of subjects: 27
Study 8985844 — intervention group
Group type: COMPARATOR
Intervention: Regular formula
Number of subjects: 27
Study 8517512 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% 25 ml
Number of subjects: 40
Study 8517512 — intervention group
Group type: COMPARATOR
Intervention: Morphine 5 mg in normal saline 25 ml
Number of subjects: 40
Study 8517512 — intervention group
Group type: COMPARATOR
Intervention: Combination of bupivacaine 0.5% 12.5 ml and 5 mg of morphine in normal saline 25 ml
Number of subjects: 40
Study 8517512 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline 25 ml
Number of subjects: 40
Study 3031840 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole 1.2 g/m2 orally on treatment day
Number of subjects: 41
Study 3031840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 3031840 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole
Number of subjects: 41
Study 29151116 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin for 3 days (Group 3)
Number of subjects: 147
Study 29151116 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin for 1 day (Group 2)
Number of subjects: 147
Study 29151116 — intervention group
Group type: COMPARATOR
Intervention: No alpha-1 blocker (Group 1)
Number of subjects: 147
Study 24886179 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavior Therapy (iCBT) program consisting of 8 weekly modules with post-session feedback support.
Number of subjects: 0
Study 24886179 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group receiving access to the treatment at week 8.
Number of subjects: 0
Study 22699254 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training (18 sessions of 20 minutes each with feedback)
Number of subjects: 18
Study 22699254 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 18
Study 20423913 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-30 with GVD (gemcitabine, vinorelbine, and pegylated liposomal doxorubicin)
Number of subjects: 30
Study 20423913 — intervention group
Group type: COMPARATOR
Intervention: Placebo with GVD (gemcitabine, vinorelbine, and pegylated liposomal doxorubicin)
Number of subjects: 30
Study 20423913 — intervention group
Group type: EXPERIMENTAL
Intervention: SGN-30 with GVD
Number of subjects: 30
Study 18602724 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal protein D (PD)-conjugate study vaccine
Number of subjects: 4968
Study 18602724 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (HAV) (control)
Number of subjects: 4968
Study 18602724 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-valent pneumococcal PD-conjugate study vaccine
Number of subjects: 4968
Study 18602724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent DTPa-HBV-IPV/Hib vaccine
Number of subjects: 4968
Study 16037183 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degrees head-up position
Number of subjects: 3
Study 16037183 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 3
Study 16037183 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 degrees head-down position
Number of subjects: 3
Study 12271279 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative imiquimod 5% cream applied for 8 weeks
Number of subjects: 12
Study 12271279 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative imiquimod 5% cream
Number of subjects: 12
Study 10332676 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple reminders (additional reminders at 3, 6, and 9 months)
Number of subjects: 19523
Study 10332676 — intervention group
Group type: COMPARATOR
Intervention: Single reminder (no additional reminders)
Number of subjects: 19523
Study 10332676 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple reminders
Number of subjects: 19523
Study 10332676 — intervention group
Group type: COMPARATOR
Intervention: Single reminder
Number of subjects: 19523
Study 7472703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiology fellows
Number of subjects: 6
Study 7472703 — intervention group
Group type: COMPARATOR
Intervention: Physician performance
Number of subjects: 6
Study 1973470 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegetarian diet, stopping smoking, stress management training, and moderate exercise
Number of subjects: 28
Study 1973470 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 28
Study 415643 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold salt treatment
Number of subjects: 79
Study 415643 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 30856689 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg daily for 4 weeks
Number of subjects: 52
Study 30856689 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 52
Study 28544504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT)
Number of subjects: 110
Study 28544504 — intervention group
Group type: COMPARATOR
Intervention: Befriending
Number of subjects: 110
Study 28544504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CBT and Befriending
Number of subjects: 110
Study 26296950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Number of subjects: 225
Study 26296950 — intervention group
Group type: COMPARATOR
Intervention: Low-flow oxygen therapy
Number of subjects: 225
Study 26296950 — intervention group
Group type: COMPARATOR
Intervention: High-flow oxygen therapy
Number of subjects: 225
Study 23668727 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation
Number of subjects: 80
Study 23668727 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflection
Number of subjects: 80
Study 23668727 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 21707627 — intervention group
Group type: EXPERIMENTAL
Intervention: Paranoid schizophrenia
Number of subjects: 374
Study 21707627 — intervention group
Group type: COMPARATOR
Intervention: Nonparanoid schizophrenia
Number of subjects: 374
Study 20023333 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient care (MOC) programme
Number of subjects: 0
Study 20023333 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to patient compliance
Number of subjects: 0
Study 20023333 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators to patient compliance
Number of subjects: 0
Study 20023333 — intervention group
Group type: EXPERIMENTAL
Intervention: General perception of the MOC programme
Number of subjects: 0
Study 16257026 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 0
Study 16257026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 0
Study 16257026 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 15564167 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam 4 g/500 mg every 8 hours
Number of subjects: 293
Study 15564167 — intervention group
Group type: COMPARATOR
Intervention: imipenem/cilastatin 500 mg/500 mg every 6 hours
Number of subjects: 293
Study 15564167 — intervention group
Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Number of subjects: 293
Study 15564167 — intervention group
Group type: COMPARATOR
Intervention: imipenem/cilastatin
Number of subjects: 293
Study 11745931 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (3 MU three times weekly for 52 weeks)
Number of subjects: 147
Study 9267858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (CCK analog)
Number of subjects: 0
Study 9267858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7970859 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking without parallel bars
Number of subjects: 0
Study 7970859 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing 40% body weight support (BWS) while walking without parallel bars
Number of subjects: 0
Study 7970859 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher treadmill speeds
Number of subjects: 0
Study 3499066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine HCl 50 mg/d
Number of subjects: 15
Study 3499066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29110963 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with simethicone (B)
Number of subjects: 120
Study 29110963 — intervention group
Group type: EXPERIMENTAL
Intervention: Water, simethicone and pronase (C)
Number of subjects: 120
Study 29110963 — intervention group
Group type: COMPARATOR
Intervention: Water alone (A)
Number of subjects: 120
Study 27600061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 75
Study 27600061 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts
Number of subjects: 75
Study 27600061 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-fat diet)
Number of subjects: 75
Study 25546985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 24
Study 25546985 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 24
Study 22631063 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐hour steroid avoidance group (n=41)
Number of subjects: 82
Study 22631063 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol group (n=41)
Number of subjects: 82
Study 21190597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dahuang Fuzi decoction enema
Number of subjects: 206
Study 21190597 — intervention group
Group type: COMPARATOR
Intervention: Soapsuds enema (control group)
Number of subjects: 206
Study 18291612 — intervention group
Group type: EXPERIMENTAL
Intervention: One-operator technique
Number of subjects: 32
Study 18291612 — intervention group
Group type: COMPARATOR
Intervention: Two-operator technique
Number of subjects: 32
Study 18291612 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 32
Study 16985020 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation
Number of subjects: 546
Study 16985020 — intervention group
Group type: COMPARATOR
Intervention: No folate supplementation
Number of subjects: 546
Study 16985020 — intervention group
Group type: EXPERIMENTAL
Intervention: TSER, TSER 3R G>C, and TS 1494del6 variants
Number of subjects: 546
Study 12838195 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation (0.3 g/kg/day)
Number of subjects: 649
Study 12838195 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (placebo)
Number of subjects: 649
Study 10668338 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization strategy (PTCA or CABG)
Number of subjects: 0
Study 10668338 — intervention group
Group type: COMPARATOR
Intervention: Ischemia-guided strategy
Number of subjects: 0
Study 10668338 — intervention group
Group type: COMPARATOR
Intervention: Revascularization strategy
Number of subjects: 0
Study 10668338 — intervention group
Group type: COMPARATOR
Intervention: Angina-guided strategy
Number of subjects: 0
Study 8842662 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 0
Study 8842662 — intervention group
Group type: COMPARATOR
Intervention: Pipecuronium
Number of subjects: 0
Study 1504160 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 14
Study 1504160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 14
Study 6857882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent leg compression
Number of subjects: 0
Study 6857882 — intervention group
Group type: COMPARATOR
Intervention: Elastic stockings
Number of subjects: 0
Study 29956215 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-Crystal of Tramadol-Celecoxib (CTC) 100 mg, 150 mg, and 200 mg administered orally
Number of subjects: 60
Study 29956215 — intervention group
Group type: COMPARATOR
Intervention: Co-Crystal of Tramadol-Celecoxib (CTC)
Number of subjects: 60
Study 29693605 — intervention group
Group type: EXPERIMENTAL
Intervention: wCDSMP
Number of subjects: 181
Study 27208375 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 25209520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozenoxacin 2% cream applied once daily (0.2 g per application)
Number of subjects: 24
Study 25209520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozenoxacin 2% cream applied twice daily (0.2 g per application, 12 h apart)
Number of subjects: 24
Study 22497803 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity water exercise program (group 1)
Number of subjects: 21
Study 22497803 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular resistance water exercise intervention (group 2)
Number of subjects: 21
Study 19129749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 100 mg
Number of subjects: 0
Study 19129749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 0
Study 19129749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 25 mg
Number of subjects: 0
Study 19129749 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 0
Study 19129749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17496672 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Communication Education (ACE) program
Number of subjects: 178
Study 17496672 — intervention group
Group type: COMPARATOR
Intervention: Placebo social program followed by ACE program
Number of subjects: 178
Study 17496672 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE program only
Number of subjects: 178
Study 15353870 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 154
Study 15353870 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 154
Study 15353870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 11601838 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg
Number of subjects: 312
Study 11601838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 9586849 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Zolpidem (Zol)
Number of subjects: 12
Study 9586849 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Diazepam (Dz)
Number of subjects: 12
Study 9586849 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Oxazepam (Ox)
Number of subjects: 12
Study 9586849 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg Zopiclone (Zop)
Number of subjects: 12
Study 9586849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (EOH; 0.65 + 0.35 g x kg(‐1))
Number of subjects: 12
Study 9586849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7989704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (800, 1000, or 1200 mg/kg per day)
Number of subjects: 18
Study 2499922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 100 micrograms twice daily
Number of subjects: 60
Study 2499922 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 60
Study 29910013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness based relapse prevention (MBRP)
Number of subjects: 79
Study 29910013 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 79
Study 28270105 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (MET-CBT)
Number of subjects: 0
Study 28270105 — intervention group
Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 0
Study 28270105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MET-CBT and brief advice
Number of subjects: 0
Study 26353424 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 500 ml of Ringers lactate
Number of subjects: 3
Study 26353424 — intervention group
Group type: COMPARATOR
Intervention: 500 ml of 6% pentastarch
Number of subjects: 3
Study 26353424 — intervention group
Group type: COMPARATOR
Intervention: Combination of 250 ml of 6% pentastarch and 750 ml of Ringers lactate
Number of subjects: 3
Study 23291800 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine daily for 8 weeks
Number of subjects: 29
Study 23291800 — intervention group
Group type: COMPARATOR
Intervention: 4 mg risperidone daily for 8 weeks
Number of subjects: 29
Study 20349169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative pedography (IP)
Number of subjects: 100
Study 20349169 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative pedography (Control)
Number of subjects: 100
Study 18782319 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 267
Study 18782319 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 267
Study 16778663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical myelopathy patients
Number of subjects: 129
Study 16778663 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 129
Study 14571612 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + TCM (Jingming recipe)
Number of subjects: 35
Study 14571612 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 35
Study 10813483 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (7-day course)
Number of subjects: 173
Study 10813483 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell trait
Number of subjects: 173
Study 10813483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed nets usage
Number of subjects: 173
Study 8986916 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg single dose)
Number of subjects: 12
Study 8986916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1454506 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 24
Study 1454506 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 3904382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (SK) therapy
Number of subjects: 39
Study 3904382 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 31054568 — intervention group
Group type: EXPERIMENTAL
Intervention: LIDO (lidocaine 1.5 mg/kg loading, 1.5 mg/kg/h infusion)
Number of subjects: 180
Study 31054568 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (dexmedetomidine 0.5 μg/kg loading, 0.4 μg/kg/h infusion)
Number of subjects: 180
Study 31054568 — intervention group
Group type: COMPARATOR
Intervention: CON (saline)
Number of subjects: 180
Study 31054568 — intervention group
Group type: EXPERIMENTAL
Intervention: LIDO
Number of subjects: 180
Study 31054568 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX
Number of subjects: 180
Study 31054568 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 180
Study 31054568 — intervention group
Group type: EXPERIMENTAL
Intervention: LIDO and DEX
Number of subjects: 180
Study 31054568 — intervention group
Group type: EXPERIMENTAL
Intervention: LIDO and CON
Number of subjects: 180
Study 30107054 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (e.g., fluoroquinolones)
Number of subjects: 262
Study 30107054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 26778006 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation therapy (ADT) (≥ 2 years)
Number of subjects: 302
Study 26778006 — intervention group
Group type: COMPARATOR
Intervention: Short-term androgen deprivation therapy (ADT) (< 2 years)
Number of subjects: 302
Study 26778006 — intervention group
Group type: COMPARATOR
Intervention: Short-term ADT
Number of subjects: 302
Study 24240712 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital cooling (infusion of up to 2 L of 4°C normal saline)
Number of subjects: 1359
Study 22467889 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose
Number of subjects: 550
Study 22467889 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 550
Study 22467889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 550
Study 20103448 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 44
Study 20103448 — intervention group
Group type: COMPARATOR
Intervention: GnRHa
Number of subjects: 44
Study 18684310 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX)‐A injections into the upper limb
Number of subjects: 22
Study 18684310 — intervention group
Group type: COMPARATOR
Intervention: Control group (no upper limb BTX‐A)
Number of subjects: 22
Study 16123721 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 80
Study 16123721 — intervention group
Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 80
Study 12100762 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 16